azelastine hydrochloride - Profile

What are the generic sources for azelastine hydrochloride and what is the scope of freedom to operate?

Azelastine hydrochloride is the generic ingredient in ten branded drugs marketed by Alembic, Apotex, Epic Pharma Llc, Gland, Sandoz, Somerset Theraps Llc, Sun Pharm, Rising, Viatris, Bayer Hlthcare, Alkem Labs Ltd, Amneal, Apotex Inc, Aurobindo Pharma Ltd, Bionpharma, Hikma, Padagis Israel, Padagis Us, Sciegen Pharms, Zydus Pharms, Aurobindo Pharma, Teva Pharms Usa Inc, and Mylan Speciality Lp, and is included in thirty-five NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Azelastine hydrochloride has fifty patent family members in twenty-four countries.

There is one tentative approval for this compound.

Summary for azelastine hydrochloride

International Patents:	50
US Patents:	2
Tradenames:	10
Applicants:	23
NDAs:	35
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for azelastine hydrochloride

Generic filers with tentative approvals for AZELASTINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		0.2055MG/SPRAY	SPRAY, METERED;NASAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for AZELASTINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CHILDREN'S ASTEPRO ALLERGY	Nasal Spray	azelastine hydrochloride	205.5 mcg/spray	213872	1	2021-07-12
ASTEPRO	Nasal Spray	azelastine hydrochloride	205.5 mcg/spray	022203		2011-12-15
OPTIVAR	Ophthalmic Solution	azelastine hydrochloride	0.05%	021127	1	2006-12-13
ASTELIN	Nasal Spray	azelastine hydrochloride	0.125 mg base/spray	020114	1	2005-11-14

US Patents and Regulatory Information for azelastine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	209620-001	Mar 20, 2019	AT	RX	No	No
Apotex	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	078621-001	Aug 3, 2009	AT	RX	No	No
Epic Pharma Llc	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	203660-001	Nov 8, 2016		DISCN	No	No
Gland	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	210092-001	Feb 25, 2020	AT	RX	No	No
Sandoz	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	202305-001	May 31, 2012	AT	RX	No	Yes
Somerset Theraps Llc	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	207411-001	Mar 29, 2019	AT	RX	No	No

Expired US Patents for azelastine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	ASTEPRO ALLERGY	azelastine hydrochloride	SPRAY, METERED;NASAL	213872-001	Jun 17, 2021
Rising	OPTIVAR	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021127-001	May 22, 2000
Viatris	ASTEPRO	azelastine hydrochloride	SPRAY, METERED;NASAL	022203-002	Aug 31, 2009
Viatris	ASTEPRO	azelastine hydrochloride	SPRAY, METERED;NASAL	022203-002	Aug 31, 2009
Bayer Hlthcare	ASTEPRO ALLERGY	azelastine hydrochloride	SPRAY, METERED;NASAL	213872-001	Jun 17, 2021
Viatris	ASTEPRO	azelastine hydrochloride	SPRAY, METERED;NASAL	022203-001	Oct 15, 2008

International Patents for azelastine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Slovenia	2522365
Slovenia	2377557
Israel	238308	תכשירי רוקחות המכילים אזלאסטין (Pharmaceutical compositions containing azelastine)
Denmark	2377557
Serbia	58377	KOMPOZICIJE KOJE SADRŽE AZELASTIN I METODE NJIHOVE UPOTREBE (COMPOSITIONS COMPRISING AZELASTINE AND METHODS OF USE THEREOF)
Japan	5607291

Supplementary Protection Certificates for azelastine hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1519731	C300740	Netherlands		PRODUCT NAME: AZELASTINE OF EEN; NAT. REGISTRATION NO/DATE: RVG114215 20141125; FIRST REGISTRATION: 2011/07125-REG 20130215
0316633	99C0012	Belgium		PRODUCT NAME: AZELASTINE HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 31 IS 113 F 13 19981021; FIRST REGISTRATION: GB PL 08336/0083 19980218
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE

Investment Scenario and Fundamentals Analysis of AZELASTINE HYDROCHLORIDE

Last updated: February 21, 2026

What Is AZELASTINE HYDROCHLORIDE?

Azelastine hydrochloride is an antihistamine used primarily to treat allergic rhinitis and conjunctivitis. It functions as a potent H1 receptor antagonist, reducing allergy symptoms. The drug is marketed in various formulations: nasal spray, eye drops, and oral tablets.

Market Overview

Global Market Valuation and Growth Projections

• In 2022, the global allergic rhinitis treatment market was valued at approximately USD 6.5 billion.
• Compound annual growth rate (CAGR): projected at 4.5% from 2023 to 2030 (Grand View Research, 2022).
• Azelastine formulations hold an estimated 25% market share, with nasal spray remaining the dominant product form.

Key Players

• Meda AB (now part of Mylan, acquired by Pfizer)
• Mylan (now part of Viatris)
• Sandoz
• Sun Pharma
• Innovative generics companies in emerging markets

Patent Landscape

• Original patents for azelastine expired around 2018–2020 in major markets.
• Several countries have generic versions approved or in development.
• No recent patents have been filed, indicating a patent cliff for branded formulations.

Investment Fundamentals

Revenue Streams

• Predominantly driven by sales of nasal spray formulations; eye drops contribute to a smaller share.
• Growth driven by:
  • Expansion in emerging markets.
  • Increased allergy prevalence.
  • Rising demand for OTC antihistamines.

Cost Structure

• Manufacturing involves complex nasal spray technology but benefits from high-volume production.
• R&D costs are relatively low due to the drug's age and generic availability.
• Marketing costs focus on physician education and OTC channels.

Regulatory Environment

• Widely approved globally, including US FDA, EMA, and other authorities.
• Generic approval is straightforward post-patent expiry.
• Emerging markets show variable regulatory standards, offering both challenges and opportunities.

Competitive Position

• Mature, with high generic competition.
• Limited scope for new patent-protected formulations.
• Opportunities exist in formulation improvements or combination therapies.

Investment Risks

• Market saturation due to high generic competition.
• Price erosion pressures from multiple manufacturers.
• Regulatory changes affecting OTC and branded drug sales.
• Potential availability of newer allergy therapies.

Strategic Considerations

• Focus on geographic expansion, especially in fast-growing emerging markets.
• Invest in branding and education to differentiate in OTC segments.
• Explore formulation innovations or combination products.

Financial Metrics and Valuation

• Due to the generic status, profit margins are tight, typically around 20-30%.
• Companies with existing distribution channels and low manufacturing costs stand to benefit most.
• Market entry barriers are low; investing in established players among multiple generic manufacturers is a common strategy.

Key Takeaways

• AZELASTINE HYDROCHLORIDE faces significant generic competition following patent expiration.
• Growth hinges on geographic expansion and increased allergy incidence.
• The drug’s mature market limits high-margin opportunities but provides steady cash flow.
• Regulatory environments are stable worldwide but vary in emerging markets.
• Strategic investments should consider scaling manufacturing, distribution, and formulation innovation.

FAQs

What is the typical patent life remaining for azelastine?
Most patents expired or are expiring between 2018 and 2022, opening the market to generics.

Are there any ongoing patent disputes or legal challenges?
No significant current patent disputes are reported for azelastine in major markets.

What are the key regulatory hurdles in emerging markets?
Variable standards may require localized clinical data and certification, prolonging approval timelines.

Can azelastine formulations be combined with other drugs?
Yes. Combination therapies with other antihistamines or corticosteroids are being explored but are not yet widespread.

How does the competitive landscape impact pricing?
Intense competition drives prices downward, pressuring profit margins, especially in markets with multiple generic manufacturers.

References

1. Grand View Research. (2022). Allergic Rhinitis Treatment Market Size, Share & Trends Analysis Report.
2. U.S. Food and Drug Administration. (2020). Patent and exclusivity data for azelastine.
3. European Medicines Agency. (2021). Marketing authorization for azelastine formulations.
4. IMS Health. (2022). Global antihistamine market trend report.
5. World Health Organization. (2021). Global allergy prevalence and treatment trends.

Note: All figures are approximate estimates based on publicly available industry data as of 2023.